VistaGen Therapeutics, Inc.
VTGN
$1.97
-$0.08-3.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -15.00K | 234.00K | 183.00K | 84.00K | 197.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.00K | 234.00K | 183.00K | 84.00K | 197.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -15.00K | 234.00K | 183.00K | 84.00K | 197.00K |
| SG&A Expenses | 4.27M | 4.05M | 4.20M | 4.57M | 4.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.48M | 15.35M | 14.41M | 12.22M | 11.56M |
| Operating Income | -14.50M | -15.12M | -14.23M | -12.13M | -11.36M |
| Income Before Tax | -13.64M | -14.09M | -12.95M | -10.73M | -9.52M |
| Income Tax Expenses | 0.00 | -- | 7.00K | -- | 1.00K |
| Earnings from Continuing Operations | -13.64M | -14.09M | -12.96M | -10.73M | -9.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.64M | -14.09M | -12.96M | -10.73M | -9.52M |
| EBIT | -14.50M | -15.12M | -14.23M | -12.13M | -11.36M |
| EBITDA | -14.46M | -15.08M | -14.19M | -12.10M | -11.33M |
| EPS Basic | -0.43 | -0.46 | -0.42 | -0.35 | -0.31 |
| Normalized Basic EPS | -0.27 | -0.29 | -0.26 | -0.22 | -0.19 |
| EPS Diluted | -0.43 | -0.46 | -0.42 | -0.35 | -0.31 |
| Normalized Diluted EPS | -0.27 | -0.29 | -0.26 | -0.22 | -0.19 |
| Average Basic Shares Outstanding | 31.56M | 30.71M | 30.63M | 30.60M | 30.52M |
| Average Diluted Shares Outstanding | 31.56M | 30.71M | 30.63M | 30.60M | 30.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |